A Phase Ib/II Study of BGJ398 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)

Trial Profile

A Phase Ib/II Study of BGJ398 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 02 Jun 2017

At a glance

  • Drugs Imatinib (Primary) ; Infigratinib (Primary)
  • Indications Gastrointestinal stromal tumours
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 02 Jun 2017 This trial has been amended to allow an alternative dosing schedule, as reported in an abstract presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
    • 02 Jun 2017 Results from Phase Ib portion of this trial (n=16) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 12 Apr 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top